Abciximab-induced thrombocytopenia: correct management
Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.
___
- 1. Nowakowski, K., et al., Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents. J Interv Cardiol, 2008. 21(1): p. 100-5.
- 2. George, J.N. and R.H. Aster, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program, 2009: p. 153-8.
- 3. Arnold, D.M., et al., A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost, 2013. 11(1): p. 169-76.
- 4. Park, S., et al., Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Korean Circ J, 2013. 43(8): p. 557-60.
- 5. Aster, R.H., et al., Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost, 2006. 4(3): p. 678-9.
- 6. Golden, T., et al., Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep, 2017. 2017.
- 7. Curtis, B.R., et al., Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost, 2004. 2(6): p. 985-92.
- 8. Aster, R.H. and D.W. Bougie, Drug-induced immune thrombocytopenia. N Engl J Med, 2007. 357(6): p. 580-7.
- 9. Llevadot, J., S.A. Coulter, and R.P. Giugliano, A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis, 2000. 9(2): p. 175-80.
- 10. Giupponi, L., et al., Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis. Platelets, 2015. 26(5): p. 498-500.
- 11. Arnold, D.M., et al., Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev, 2013. 27(3): p. 137-45.
- 12. Bakchoul, T. and I. Marini, Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program, 2018. 2018(1): p. 576-583.
- 13. Piątek, Ł., et al., Delayed severe abciximab-induced thrombocytopenia: A case report. Heart Lung, 2016. 45(5): p. 464-5.
- Yayın Aralığı: Yılda 4 Sayı
- Başlangıç: 1980
- Yayıncı: Ondokuz mayıs Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler
Şeyma AKKUŞ, Ali Haydar AKÇA, Gizem GİZLİ
Zehra YILMAZ, Huri GÜVEY, Samettin ÇELİK, Canan SOYER ÇALIŞKAN
Kemal Çağlar DURAN, Recep DİNÇER, Tolga ATAY, Vecihi KIRDEMİR
Azar ABİYEV, Serkan DUMANLI, Mustafa ERGİN, Mehmet İBİŞ
Irfan AFZAL MUGHAL, Noor-ul-ain IRFAN, Saira SAFDAR, Sadia MOAZZAM, Asma IRFAN, Amna FAROOQİ, Muhammad ISMAİL
Batuhan GENCER, Ahmet ÇULCU, Özgür DOĞAN
Dursun Fırat ERGÜL, Maruf BORAN
Nazlı TOPFEDAİSİ ÖZKAN, İbrahim YALÇIN, Mehmet Mutlu MEYDANLI
Nedim TOKGOZOGLU, Orhan SAHIN, Tolga TAŞÇI, Nur DOKUZEYLÜL GÜNGÖR